Compare Ryanair Holdings plc (RYAAY) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ryanair Holdings plc vs Sanofi SA — how do they compare? Ryanair Holdings plc trades at $59.39 (market cap $29.63B), while Sanofi SA trades at $43.61 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 3.5× Ryanair Holdings plc's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| RYAAY | SNY | |
|---|---|---|
Market Cap | $29.63B | $104.30B |
Sector | Industrials | Health |
52-Week High | $73.82 | $52.34 |
52-Week Low | $53.24 | $41.33 |
Enterprise Value | $26.61B | $124.19B |
Dividend Yield | 1.51% | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ryanair Holdings (RYAAY) trades at $59.41, down 0.17% with bearish technical signals despite reasonable valuations (P/E 14.37). The airline reported mixed quarterly results with Q1 2026 beating expectations but Q2 2026 missing, while maintaining strong profitability (22.41% ROE) and a solid balance sheet with $3.96B cash. Recent news highlights operational challenges from lower fares and fuel costs, alongside strategic AI partnerships.
Outlook remains cautious due to near-term headwinds from fare pressure and geopolitical risks, but long-term prospects are supported by industry consolidation potential and strong financials. Analyst consensus is bullish (62.5% Buy ratings), viewing current weakness as overdone. Key risks include fuel price volatility and competitive dynamics.
SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.
Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
